[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585579":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":62,"collaborators":25,"id":64,"slug":25,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Len+SIRT","EXPERIMENTAL","Lenvatinib plus SIRT",[13],"Combination Product: Lenvatinib plus SIRT",{"label":15,"type":16,"description":17,"interventionNames":18},"LEN","ACTIVE_COMPARATOR","Lenvatinib alone",[19],"Drug: Lenvatinib",[21,26],{"type":22,"name":11,"description":23,"armGroupLabels":24,"otherNames":25},"COMBINATION_PRODUCT","Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \\\u003C60kg) P.O. QD will be started at 3-7 days after the first SIRT.",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DRUG","Lenvatinib","Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \\\u003C60kg) P.O. QD.",[15],[32],{"name":33,"affiliation":5,"role":34},"Mingyue Cai, Dr.","STUDY_CHAIR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":25,"email":39},"CONTACT","+86-20-34156205","cai020@yeah.net",{"name":33,"role":37,"phone":38,"phoneExt":25,"email":41},"zhksh010@163.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"The Second Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","510260","China",{"type":51,"coordinates":52},"Point",[53,54],113.25,23.11667,{"lat":54,"lon":53},[57,58,60],{"name":33,"role":37,"phone":38,"phoneExt":25,"email":39},{"name":59,"role":37,"phone":38,"phoneExt":25,"email":41},"Kangshun Zhu, Dr.",{"name":59,"role":61,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":63,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100585579",false,"NCT06904196","Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC","Lenvatinib Combined With Yttrium-90 Selective Internal Radiation Therapy (SIRT) Versus Lenvatinib Alone in TACE-Refractory Hepatocellular Carcinoma: A Prospective Non-Randomized Controlled Study","Inclusion Criteria:\n\n* Pathologically confirmed or clinically diagnosed HCC\n* Diagnosis of HCC with TACE refractoriness according to the criteria proposed by Japan Society of Hepatology (2021)\n* Patients who have Tumor recurrence after surgical resection or ablation are allowed to be included\n* At least one measurable intrahepatic target lesion\n* Child-Pugh class A\u002FB\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Tumor extent \\\u003C70% liver occupation\n* Candidates for SIRT must be confirmed suitable for SIRT after evaluation (including SPECT\u002FCT evaluation after arterial perfusion with 99Tc-MAA)\n* Adequate organ and hematologic function with platelet count ≥50×10\\^9\u002FL, leukocyte \\>3.0×10\\^9\u002FL, Neutrophil count ≥1.5×10\\^9\u002FL, haemoglobin ≥85 g\u002FL, ALT and AST≤5×ULN, albumin ≥28 g\u002FL, total bilirubin ≤3× ULN, creatinine≤1.5×ULN, and prolongation of prothrombin time ≤4 seconds\n* Life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Extrahepatic metastasis\n* Tumor thrombus involving main portal vein or both the first left and right branches of portal vein\n* Vena cava invasion\n* Patients who received prior hepatic arterial infusion chemotherapy (HAIC), radiotherapy, or systemic therapy, for HCC\n* History of organ and cell transplantation\n* History of esophageal or gastric variceal bleeding\n* History of hepatic encephalopathy\n* History of other malignancies\n* Human immunodeficiency virus infection","ALL","18 Years","75 Years",{"count":74,"type":75},78,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).",[81],"Hepatocellular Carcinoma Non-resectable",[83,28,84],"hepatocellular carcinoma","Yttrium-90","2025-04-28",{"date":87,"type":88},"2025-04-29","ACTUAL",{"date":90,"type":88},"2025-04-01",{"date":92,"type":75},"2029-03-31",{"name":5,"class":6},1]